1. ImmunityBio's $100M public offering supports ANKTIVA's commercialization and pipeline programs; 2. Despite dilution and lower offering price, ANKTIVA's performance and future milestones could drive substantial growth; 3. Financial risks persist, but potential for explosive revenue growth supports a bullish outlook.